SLC12A4

Across TCGA pan-cancer cohorts, SLC12A4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC12A4 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC12A4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC12A4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and ESCA show a favorable association.

STAD, UCEC, and PRAD are the cancer types where SLC12A4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.218	0.631	.009	12	view →
UCEC	DFS	Median	All	0.959	0.825	.011	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
ESCA	OS	Median	II,III,IV	0.528	0.492	.005	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC12A4–STAD (DFS)

Open the STAD breakdown →